ARTICLE | Editor's Commentary
2026 U.S. drug pricing outlook: ‘MFN’ is the future
Once unthinkable, pegging U.S. prices to international benchmarks will become routine
January 15, 2026 9:03 PM UTC
PhRMA is entering 2026 in a quiet panic.
The trade association’s leaders are calling members of Congress, urging them to resist President Donald Trump’s demands for legislation codifying “most favored nation” (MFN) drug pricing. The conversations are uncomfortable. Many of the CEOs making those calls publicly praised MFN in Oval Office meetings with Trump. ...
BCIQ Company Profiles